Article
Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.
European journal of cancer (Oxford, England : 1990) - 26 Aug 2026
Verbeek Florentine A J, Martinez Miguel P, Spiekman Ilse A C, Verkerk Karlijn, Haj Mohammad Soemeya F, Timmer Hans, van Maren Maud A, Zeverijn Laurien J, Geurts Birgit S, van der Noort Vincent, Roepman Paul, Jansen Anne M L, de Leng Wendy W J, Theelen Willemijn S M E, Piet Berber, Gelderblom Hans, Verheul Henk M W, Voest Emile E
Abstract excerpt
BACKGROUND: NRAS-mutations occur in about 3% of all cancers. Currently, no Food and Drug Administration- (FDA) or European Medicines Agency- (EMA)-approved therapy exists for patients harboring NRAS-mutated malignancies. Trametinib, a MEK1/2 inhibitor, could elicit clinical benefit (CB) in patients harboring NRAS mutations by blocking the MAPK pathway. In the Drug Rediscovery Protocol (DRUP; NCT02925234), we...
Topics
- Adult
- Aged
- Aged, 80 and over
- Female
- Humans
- Male
- Middle Aged
- Antineoplastic Agents
- GTP Phosphohydrolases
- Membrane Proteins
- Mutation
- Neoplasms